622 related articles for article (PubMed ID: 23811112)
1. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
Marcellin P; Cooper C; Balart L; Larrey D; Box T; Yoshida E; Lawitz E; Buggisch P; Ferenci P; Weltman M; Labriola-Tompkins E; Le Pogam S; Nájera I; Thomas D; Hooper G; Shulman NS; Zhang Y; Navarro MT; Lim CY; Brunda M; Terrault NA; Yetzer ES
Gastroenterology; 2013 Oct; 145(4):790-800.e3. PubMed ID: 23811112
[TBL] [Abstract][Full Text] [Related]
2. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
3. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders.
Gane EJ; Rouzier R; Wiercinska-Drapalo A; Larrey DG; Morcos PN; Brennan BJ; Le Pogam S; Nájera I; Petric R; Tran JQ; Kulkarni R; Zhang Y; Smith P; Yetzer ES; Shulman NS
Antimicrob Agents Chemother; 2014; 58(2):1136-45. PubMed ID: 24295986
[TBL] [Abstract][Full Text] [Related]
5. Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.
Feld JJ; Jacobson IM; Jensen DM; Foster GR; Pol S; Tam E; Jablkowski M; Berak H; Vierling JM; Yoshida EM; Perez-Gomez HR; Scalori A; Hooper GJ; Tavel JA; Navarro MT; Shahdad S; Kulkarni R; Le Pogam S; Nájera I; Eng S; Lim CY; Shulman NS; Yetzer ES
J Hepatol; 2015 Feb; 62(2):294-302. PubMed ID: 25239078
[TBL] [Abstract][Full Text] [Related]
6. Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis.
Kao JH; Tung SY; Lee Y; Thongsawat S; Tanwandee T; Sheen IS; Wu JJ; Li H; Brennan BJ; Zhou J; Le Pogam S; Najera I; Thommes JA; Hill G
J Gastroenterol Hepatol; 2016 Oct; 31(10):1757-1765. PubMed ID: 26992248
[TBL] [Abstract][Full Text] [Related]
7. Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon-α2a (40 KD) plus ribavirin.
Larrey D; Carenco C; Guyader D; Boyer N; Benhamou Y; Pageaux GP; Rouzier R; Marcellin P
Antivir Ther; 2012; 17(5):927-32. PubMed ID: 22611092
[TBL] [Abstract][Full Text] [Related]
8. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.
Rossignol JF; Elfert A; El-Gohary Y; Keeffe EB
Gastroenterology; 2009 Mar; 136(3):856-62. PubMed ID: 19135998
[TBL] [Abstract][Full Text] [Related]
9. DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4.
Everson G; Cooper C; Hézode C; Shiffman ML; Yoshida E; Beltran-Jaramillo T; Andreone P; Bruno S; Ferenci P; Zeuzem S; Brunda M; Le Pogam S; Nájera I; Zhou J; Navarro MT; Voulgari A; Shulman NS; Yetzer ES
Liver Int; 2015 Jan; 35(1):108-19. PubMed ID: 24517252
[TBL] [Abstract][Full Text] [Related]
10. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.
Shiffman ML; Suter F; Bacon BR; Nelson D; Harley H; Solá R; Shafran SD; Barange K; Lin A; Soman A; Zeuzem S;
N Engl J Med; 2007 Jul; 357(2):124-34. PubMed ID: 17625124
[TBL] [Abstract][Full Text] [Related]
11. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.
Gane EJ; Rouzier R; Stedman C; Wiercinska-Drapalo A; Horban A; Chang L; Zhang Y; Sampeur P; Nájera I; Smith P; Shulman NS; Tran JQ
J Hepatol; 2011 Nov; 55(5):972-9. PubMed ID: 21354234
[TBL] [Abstract][Full Text] [Related]
12. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.
Flamm SL; Lawitz E; Jacobson I; Bourlière M; Hezode C; Vierling JM; Bacon BR; Niederau C; Sherman M; Goteti V; Sings HL; Barnard RO; Howe JA; Pedicone LD; Burroughs MH; Brass CA; Albrecht JK; Poordad F
Clin Gastroenterol Hepatol; 2013 Jan; 11(1):81-87.e4; quiz e5. PubMed ID: 23064222
[TBL] [Abstract][Full Text] [Related]
13. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
Dore GJ; Lawitz E; Hézode C; Shafran SD; Ramji A; Tatum HA; Taliani G; Tran A; Brunetto MR; Zaltron S; Strasser SI; Weis N; Ghesquiere W; Lee SS; Larrey D; Pol S; Harley H; George J; Fung SK; de Lédinghen V; Hagens P; McPhee F; Hernandez D; Cohen D; Cooney E; Noviello S; Hughes EA
Gastroenterology; 2015 Feb; 148(2):355-366.e1. PubMed ID: 25311593
[TBL] [Abstract][Full Text] [Related]
14. Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C.
Forestier N; Larrey D; Marcellin P; Guyader D; Patat A; Rouzier R; Smith PF; Qin X; Lim S; Bradford W; Porter S; Seiwert SD; Zeuzem S
J Infect Dis; 2011 Aug; 204(4):601-8. PubMed ID: 21791662
[TBL] [Abstract][Full Text] [Related]
15. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
Ascione A; De Luca M; Tartaglione MT; Lampasi F; Di Costanzo GG; Lanza AG; Picciotto FP; Marino-Marsilia G; Fontanella L; Leandro G
Gastroenterology; 2010 Jan; 138(1):116-22. PubMed ID: 19852964
[TBL] [Abstract][Full Text] [Related]
16. Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads.
Reddy KR; Shiffman ML; Rodriguez-Torres M; Cheinquer H; Abdurakhmanov D; Bakulin I; Morozov V; Silva GF; Geyvandova N; Stanciu C; Rabbia M; McKenna M; Thommes JA; Harrison SA;
Gastroenterology; 2010 Dec; 139(6):1972-83. PubMed ID: 20816836
[TBL] [Abstract][Full Text] [Related]
17. Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study.
Gane EJ; Pockros PJ; Zeuzem S; Marcellin P; Shikhman A; Bernaards C; Zhou J; Yetzer ES; Ballester R; Dwyer C; Tong X; Nájera I; Bertasso A; Hammond J; Kindrick A; Morcos PN; Smith P; Stancic S; Shulman NS
Liver Int; 2015 Jan; 35(1):79-89. PubMed ID: 24814388
[TBL] [Abstract][Full Text] [Related]
18. Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis.
Gane EJ; Rouzier R; Hassanein T; Stedman CA; Mazur W; Kupcova V; Le Pogam S; Eng S; Voulgari A; Morcos PN; Brennan BJ; Scalori A; Thommes J
Hepatol Int; 2016 May; 10(3):478-87. PubMed ID: 26886127
[TBL] [Abstract][Full Text] [Related]
19. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial.
Hayashi N; Izumi N; Kumada H; Okanoue T; Tsubouchi H; Yatsuhashi H; Kato M; Ki R; Komada Y; Seto C; Goto S
J Hepatol; 2014 Aug; 61(2):219-27. PubMed ID: 24727123
[TBL] [Abstract][Full Text] [Related]
20. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
Reddy KR; Zeuzem S; Zoulim F; Weiland O; Horban A; Stanciu C; Villamil FG; Andreone P; George J; Dammers E; Fu M; Kurland D; Lenz O; Ouwerkerk-Mahadevan S; Verbinnen T; Scott J; Jessner W
Lancet Infect Dis; 2015 Jan; 15(1):27-35. PubMed ID: 25482330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
